TY - JOUR
T1 - Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer
AU - Grützmeier, Simon Ezban
AU - Kovacevic, Bojan
AU - Vilmann, Peter
AU - Rift, Charlotte Vestrup
AU - Melchior, Linea Cecilie
AU - Holmström, Morten Orebo
AU - Brink, Lene
AU - Hassan, Hazem
AU - Karstensen, John Gásdal
AU - Grossjohann, Hanne
AU - Chiranth, Deepthi
AU - Toxværd, Anders
AU - Hansen, Carsten Palnæs
AU - Høgdall, Estrid
AU - Hasselby, Jane Preuss
AU - Klausen, Pia
PY - 2023/7/19
Y1 - 2023/7/19
N2 - Cancer-associated fibroblasts (CAFs) have been shown to impact the chemosensitivity of patient-derived tumor organoids (PDTOs). However, the published literature comparing PDTO response to clinical outcome does not include CAFs in the models. Here, a co-culture model was created using PDTOs and CAFs derived from endoscopic ultrasound-guided fine-needle biopsies (EUS-FNBs) for potential use in drug screening applications. Co-cultures were established, and growth was compared to monocultures using image metrics and a commercially available assay. We were able to establish and expand validated malignant PDTOs from 19.2% of adenocarcinomas from EUS-FNBs. CAFs could be established from 25% of the samples. The viability of PDTOs in the mixed cell co-culture could be isolated using image metrics. The addition of CAFs promoted PDTO growth in half of the established co-cultures. These results show that co-cultures can be established from tiny amounts of tissue provided by EUS-FNB. An increased growth of PDTOs was shown in co-cultures, suggesting that the present setup successfully models CAF-PDTO interaction. Furthermore, we demonstrated that standard validation techniques may be insufficient to detect contamination with normal cells in PDTO cultures established from primary tumor core biopsies.
AB - Cancer-associated fibroblasts (CAFs) have been shown to impact the chemosensitivity of patient-derived tumor organoids (PDTOs). However, the published literature comparing PDTO response to clinical outcome does not include CAFs in the models. Here, a co-culture model was created using PDTOs and CAFs derived from endoscopic ultrasound-guided fine-needle biopsies (EUS-FNBs) for potential use in drug screening applications. Co-cultures were established, and growth was compared to monocultures using image metrics and a commercially available assay. We were able to establish and expand validated malignant PDTOs from 19.2% of adenocarcinomas from EUS-FNBs. CAFs could be established from 25% of the samples. The viability of PDTOs in the mixed cell co-culture could be isolated using image metrics. The addition of CAFs promoted PDTO growth in half of the established co-cultures. These results show that co-cultures can be established from tiny amounts of tissue provided by EUS-FNB. An increased growth of PDTOs was shown in co-cultures, suggesting that the present setup successfully models CAF-PDTO interaction. Furthermore, we demonstrated that standard validation techniques may be insufficient to detect contamination with normal cells in PDTO cultures established from primary tumor core biopsies.
KW - EUS-FNB
KW - cancer-associated fibroblasts
KW - co-cultures
KW - disease modelling
KW - pancreatic cancer
KW - patient-derived organoids
KW - personalized medicine
UR - http://www.scopus.com/inward/record.url?scp=85167856554&partnerID=8YFLogxK
U2 - 10.3390/cancers15143677
DO - 10.3390/cancers15143677
M3 - Journal article
C2 - 37509338
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 14
M1 - 3677
ER -